UNSPSC 51332845: Chlorpromazine sulphoxide

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C17H19ClN2OS, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 016U10PN9N, chemically known as 2-chloro-10-(3-(dimethylamino)propyl)phenothiazine 5-oxide, but more generally known as chlorpromazine sulphoxide, which bears US NIH Compound Identifier 70413. European Medicines Agency schedules chlorpromazine sulphoxide or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06208MIG.

Most nations, for tariff purposes, schedule chlorpromazine sulphoxide under HS 29343090. SMILES: CN(C)CCCN1C2CCCCC2[S+](C3C1CC(CC3)CL)[O-].

UNSPSC 51332845 Chlorpromazine sulphoxide, a Commodity code, does not align with the recent state and local procurement activity tagged under it. The three recent opportunities solicited under this code involve naloxone and drug deactivation systems, therapeutic pharmacy initiatives and direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals and over-the-counter products — none of which are chlorpromazine sulphoxide or closely related pharmaceutical active ingredients. The mismatch suggests either a coding error in the source records or a tagging convention that bundles disparate pharmaceutical procurement under a single code. Based on what is actually being solicited, state and local buyers under this code designation are procuring community health supplies (naloxone kits), information on direct pharmacy contracting models, and wholesale generic pharmaceutical products through cooperative purchasing agreements.

The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances administering pharmaceuticals across multiple jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota and Oregon). Recent opportunities span the Southeast (Florida), Southwest (Texas), and Upper Midwest (Minnesota and Oregon). Representative recent solicitations include Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023; Texas HHS Commission's RFI HHS0017013 exploring direct-to-manufacturer prescription contracting, due April 3, 2026; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026.